<DOC>
	<DOCNO>NCT00764998</DOCNO>
	<brief_summary>The purpose research study : 1. see difference quantity protective influenza antibody produce different dos Fluviral vaccine 2. see different vaccine dose schedule reduce flu-like illness and/or reduce laboratory document influenza HIV Infected adult .</brief_summary>
	<brief_title>Influenza Vaccine HIV</brief_title>
	<detailed_description>Immune compromise individual risk infection influenza likely manifest severe symptom influenza disease . Furthermore , influenza vaccine hyporesponsive comparison healthy , adult immune competent individual . One population immune compromise Canadians risk severe influenza disease live HIV infection . At least 56,000 Canadians HIV infect [ 1 ] . This population risk severe influenza illness . Influenza viral replication shed prolonged duration influenza symptomatology longer HIV [ 2 , 3 ] . Furthermore , influenza-related mortality rate HIV infected individual increase [ 4 ] . The HIV population know hyporesponsive vaccination , include influenza . The efficacy influenza vaccine compromise , part , reduce antibody response observe HIV infected individual [ 5 ] . Nevertheless , influenza vaccination recommend HIV-infected individual [ 6 , 7 ] . The Centers Disease Control guideline state : `` Influenza result serious illness vaccination inactivate influenza vaccine might result production protective antibody titer , vaccination might benefit HIV-infected person . Therefore , influenza vaccination recommend '' . As influenza vaccination cornerstone public health intervention intend protect population influenza , vaccine hyporesponsiveness immune compromise population represent significant concern . Given risk influenza exposure general well concern related poor vaccine efficacy severe influenza disease immune compromise population live HIV , strategy improve vaccine efficacy require . Therefore total 5 condition provide justification trial conduct time : 1. current standard treatment influenza vaccine less efficacious use particular subgroup immune compromise individual , diagnose HIV 2. exist significant burden influenza infection HIV patient must address term identify effective treatment strategy 3. past randomize trial influenza vaccination HIV patient limited comparability today 's relevant base patient , alternative vaccination strategy require assessment 4. efficacy booster dose influenza vaccine HIV patient remain question consequence methodologic shortcoming term design aspects outcomes measure past study 5. paucity publish evidence assess efficacy increase , double-dose influenza vaccine patient population . References 1 . Boulos , D. , et al. , Estimates HIV prevalence incidence Canada , 2005 . Can Commun Dis Rep , 2006 . 32 ( 15 ) : p. 165-74 . 2 . Safrin , S. , J.D . Rush , J . Mills , Influenza patient human immunodeficiency virus infection . Chest , 1990 . 98 ( 1 ) : p. 33-7 . 3 . Radwan , H.M. , et al. , Influenza human immunodeficiency virus-infected patient 1997-1998 influenza season . Clin Infect Dis , 2000 . 31 ( 2 ) : p. 604-6 . 4 . Zanetti , A.R. , et al. , Safety immunogenicity influenza vaccination individual infect HIV . Vaccine , 2002 . 20 Suppl 5 : p. B29-32 . 5 . Malaspina , A. , et al. , Compromised B cell response influenza vaccination HIV-infected individual . J Infect Dis , 2005 . 191 ( 9 ) : p. 1442-50 . 6 . Health Canada Progress towards Canadian target coverage rate Influenza Pneumococcal Immunications. , Available : http : //www.phac-aspc.gc.ca/publicat/ccdr-rmtc/01vol27/dr2710eb.htlm . Accessed 8 December 2006 . 2006 . 7 . Prevention Control Influenza . Recommendations advisory committee immunization practice , Centers Disease Control Prevention . Morbidity Morality Weekly Report . 2006. p. Vol 55/RR-10 .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Age 18 &lt; 60 year HIV positive Able provide sign , informed consent . Receipt anticipate requirement blood product , vaccine , immunoglobulin preparation within one month study vaccine administration completion study . Immunosuppressive therapy include prednisone , immune modulators , subject undergoing dialysis , autoimmune dysfunction ( include rheumatoid arthritis , lupus erythematosus , multiple sclerosis ) Alcohol consumption &gt; 4 drink per day ( 1 drink equal 12ounce beer , 5ounce glass wine one cocktail 1 1/2ounces alcohol ) History cancer , exception cutaneous cancer include Kaposi Sarcoma , basal cell carcinoma noninvasive HPVrelated malignancy Known suspect hypersensitivity component study vaccine , include chicken egg egg product thimerosol History immediate hypersensitivity reaction and/or reaction result neurological symptom previous dose influenza vaccine Presentation recent history ( within 24 hour ) febrile illness ( &gt; 38 C ) symptoms significant local systemic infection subject defer enrollment least one week illness resolve Any condition opinion Investigator might interfere evaluation study objective .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Influenza</keyword>
	<keyword>HIV</keyword>
	<keyword>Influenza Vaccine</keyword>
	<keyword>Efficacy</keyword>
</DOC>